



Comsortium: buyers and partners





The public need to be tackled...

Support the patient's adherence and minimize non-adherence

194,500 deaths per year in EU due to misdose/non-adherence of prescribed medication

Non-adherence is estimated to cost the European Union €1.25 billion annually





EMPATTICS approach

- Implementing ICT technologies to support patient empowerment and improve adherence
- An intervention that encompasses multiple levels:
- Help patients to develop healthy adaptive behaviors to change the problematic ones
 - Better communication between patients and health professionals
 - Awareness and knowledge about adherence
 - Tools to support adherence
 - Information for self-care





But we don't know the technology...

We want a Flexible Adherence Plattform valid for multiple disease...



... through the Precomercial Public Procurenment process



PCP phases

Phase 1 (4 months) M13-M16

 Project plan about the viability of the proposal

Total budget 250.000€

 Expecting 10 companies (max. budget 25.000€ per company)

Phase 2 (9 months) M18-M27

- Development of prototype of the solution proposed in Phase1
- Total budget 1.650.000€
- Expecting 5 companies (max. budget 330.000€ per company).

å empattics

Phase 3 (8 months) M28-M36

- Development of a full demonstrator and its validation with patients.
- Total budget 1,6M€.
- Expecting 3 companies (max budget 533.000€ per company)

What PCP means




PCP Pre-Commercial Procurement

- When
 - Challenge requires R&D to get new solutions developed. Problem clear, but pros / cons of several potential competing solutions not compared / validated yet. No commitment to deploy (PPI) yet.
- What
 - Public sector buys R&D to steer development of solutions to its needs, gather knowledge about pros / cons of alternative solutions, to avoid supplier lock-in later (create competitive supply base)
- How
 - Public sector buys R&D from several suppliers in parallel (comparing alternative solution approaches), in form of competition evaluating progress after critical milestones (design, prototyping, test phase), risks & benefits of R&D (e.g. IPRs) shared with suppliers to maximise incentives for wide commercialisation



Several companies and technologies participate






Expected outcomes

- Ending with 3 flexible and generic solutions that will increase adherence using ICT self-care technologies and will encourage professionals to use decision support systems.
- Empattics will test these best solutions for three diseases
 Diabetes, COPD and insufficiency cardiac.
- Validations with patients and within health systems accross Europe



Timeline















EMpowering PAtients for a BeTTer Information and improvement of the Communication Systems

GA n.º 690492





















EMpowering PAtients for a BeTTer Information and improvement of the Communication Systems

GA n.º 690492



